Tissue-sparing laser therapy successfully treats DME

Article

Iridex Corporation have announced the results of a 10 year study confirming the safety and efficacy of using MicroPulse laser therapy for the treatment of diabetic macular oedema (DME).

Iridex Corporation have announced the results of a 10 year study confirming the safety and efficacy of using MicroPulse laser therapy for the treatment of diabetic macular oedema (DME).

The investigation, compiled by Dr Jeffrey K. Luttral et al., Ventura County Retina Vitreous Medical Group, California, USA, included 252 eyes with macular oedema. The study group consisted of 212 eyes with diabetic retinopathy and 40 eyes with branch retinal vein occlusion. Of the patients studied, 181 met the inclusion criteria and underwent subvisible MicroPulse laser treatment, with a follow-up of 10 years.

Dr Luttrall said, "MicroPulse laser therapy is an ideal first-line treatment for retinal vascular macular oedema because of its unique safety profile. Using specific laser parameters discussed in our recent study, MicroPulse laser treatment can be performed.

"I believe this laser treatment to be both absolutely harmless and as effective as conventional thermal retinal photocoagulation. The laser is able to produce the desired therapeutic effect without any measurable inflammation or damage to functional retinal tissue. Treatment can be initiated earlier, possibly improving long-term outcomes."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.